New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma. Issue 8 (2nd August 2016)

• Record Type: Journal Article
• Authors: Merli, Michele; Ferrario, Andrea; Maffioli, Margherita; Olivares, Cecilia; Stasia, Alessandra; Arcaini, Luca; Passamonti, Francesco
• Is Part Of: Expert review of hematology. Volume 9:Issue 8(2016)
• Page Start: 767
• Page End: 780
• Publication Date: 2016-08-02
• Subjects: Antibody-drug conjugates -- brentuximab vedotin -- CD30 -- Hodgkin lymphoma -- non-peripheral T-cell lymphoma -- cutaneous T-cell lymphoma -- diffuse large B-cell lymphoma -- polatuzumab vedotin; Hematology -- Periodicals; 616.15005
• DOI: 10.1080/17474086.2016.1205949
• Languages: English
• ISSNs: 1747-4086

Abstract

ABSTRACT: Introduction : Brentuximab vedotin (BV) is a potent anti-CD30 antibody drug conjugate (ADC) that has been approved in relapsed or refractory Hodgkin lymphoma (HL) after autologous stem cell transplantation (ASCT) and anaplastic large-cell lymphoma (ALCL). Beyond these consolidated indications, BV has been tested in a number of different settings with promising results, leading for example to the recent approval as a consolidation after ASCT in high-risk HL patients. Areas covered : Main emerging areas of clinical investigation of BV include the use as a single-agent or in combination with bendamustine in first-salvage therapy of HL (bridge to ASCT), in the frontline setting in combination with AVD chemotherapy in HL and with CHP in ALCL, in relapsed or refractory cutaneous T-cell lymphomas and finally in diffuse large B-cell lymphomas (DLBCL) expressing CD30. Moreover, many new ADCs are currently under clinical evaluation, as for example the anti-CD79A polatuzumab vedotin in DLBCL. Expert commentary : In few years BV changed the therapeutic scenario of relapsed or refractory HL and ALCL and is rapidly moving toward first-line approval in combination with standard chemotherapy if ongoing randomized trials will demonstrate improved results. Combination strategies with bendamustine in first-salvage HL and with R-CHP in first-line DLBCL appear very promising.